Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp

Tebentafusp, a bispecific immune therapy, is the only drug that demonstrated an overall survival benefit in patients with metastatic uveal melanoma (MUM). Circulating tumor DNA (ctDNA) has emerged as a potential prognostic and predictive marker in the phase 3 IMCgp100-202 trial using multiplex PCR-b...

Full description

Saved in:
Bibliographic Details
Published in:Nature communications 2024-10, Vol.15 (1), p.8851-10, Article 8851
Main Authors: Rodrigues, Manuel, Ramtohul, Toulsie, Rampanou, Aurore, Sandoval, José Luis, Houy, Alexandre, Servois, Vincent, Mailly-Giacchetti, Léah, Pierron, Gaelle, Vincent-Salomon, Anne, Cassoux, Nathalie, Mariani, Pascale, Dutriaux, Caroline, Pracht, Marc, Ryckewaert, Thomas, Kurtz, Jean-Emmanuel, Roman-Roman, Sergio, Piperno-Neumann, Sophie, Bidard, François-Clément, Stern, Marc-Henri, Renault, Shufang
Format: Article
Language:English
Subjects:
45/77
631/67/1059/2325
631/67/1484
631/67/1857
Adult
Aged
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
Chemical Sciences
Circulating Tumor DNA - blood
Circulating Tumor DNA - genetics
Deoxyribonucleic acid
DNA
Droplets
Female
High-Throughput Nucleotide Sequencing - methods
Humanities and Social Sciences
Humans
Male
Medical prognosis
Melanoma
Melanoma - blood
Melanoma - drug therapy
Melanoma - genetics
Melanoma - pathology
Melanoma - secondary
Metastases
Metastasis
Middle Aged
multidisciplinary
Neoplasm Metastasis
Next-generation sequencing
Polymerase chain reaction
Prognosis
Prospective Studies
Science
Science (multidisciplinary)
Survival
Tumors
Uveal Neoplasms - blood
Uveal Neoplasms - genetics
Uveal Neoplasms - pathology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tebentafusp, a bispecific immune therapy, is the only drug that demonstrated an overall survival benefit in patients with metastatic uveal melanoma (MUM). Circulating tumor DNA (ctDNA) has emerged as a potential prognostic and predictive marker in the phase 3 IMCgp100-202 trial using multiplex PCR-based next-generation sequencing (NGS). In this study (NCT02866149), ctDNA dynamics were assessed using droplet digital PCR (ddPCR) in 69 MUM patients undergoing tebentafusp treatment. Notably, 61% of patients exhibited detectable ctDNA before treatment initiation, which was associated with shorter overall survival (median 12.9 months versus 40.5 months for patients with undetectable ctDNA; p  
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-024-53145-0